The deal – which could be worth up to $2.2 billion if PRX005 reaches the market – comes nearly a decade after BMS all-but exited the category after abandoning amyloid-targeting drug avagacestat.
10+ additional apps for your business needs (Microsoft Bookings, Planner, Forms, and others) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback